Skip to main content
PMC home page
Immunology logoLink to Immunology
. 1990 Feb;69(2):222–227.

Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506.

K Yamamoto 1, A Mori 1, T Nakahama 1, M Ito 1, H Okudaira 1, T Miyamoto 1
PMCID: PMC1385593  PMID: 1689694

Abstract

A newly developed immunosuppressive drug, FK506 (Fujisawa, Japan) is known to inhibit T-cell immunity. We have evaluated the action of this compound in MRL/lpr mice which develop a severe autoimmune disease. Eight-week-old female MRL/lpr of mice were treated subcutaneously with 2 mg/kg (high dose), 0.8 mg/kg (medium dose), 0.2 mg/kg (low dose) or solvent only (control) six times per week. Survival times of the mice were prolonged in the medium and the high dose treatment groups. The lymph node swelling was dramatically prevented with the high dose treatment. The increasing footpad swelling seemed to be also suppressed with the treatment. FACS analyses of the spleen cells revealed that FK506 reduced the percentage of double negative T cells (Thy-1.2+, Lyt-2-, L3T4-). Serological studies showed that anti-ssDNA and anti-dsDNA activities were significantly reduced by the high dose treatment, which is different from recent findings with Cyclosporine A. The high dose treatment also suppressed the total amount of IgG, even though the IgG concentration was rather increased by the medium dose treatment. Decreased proteinuria as well as pathological evaluations of the kidneys and lungs indicated that there were marked ameliorations in these organs with the treatment. These results suggest that FK506 could be potentially used for the treatment of autoimmune diseases.

Full text

PDF
226

Images in this article

225Figure 5
on p.225

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews B. S., Eisenberg R. A., Theofilopoulos A. N., Izui S., Wilson C. B., McConahey P. J., Murphy E. D., Roths J. B., Dixon F. J. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med. 1978 Nov 1;148(5):1198–1215. doi: 10.1084/jem.148.5.1198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beach R. S., Gershwin M. E., Hurley L. S. Nutritional factors and autoimmunity. III. Zinc deprivation versus restricted food intake in MRL/1 mice--the distinction between interacting dietary influences. J Immunol. 1982 Dec;129(6):2686–2692. [PubMed] [Google Scholar]
  3. Borel Y., Lewis R. M., André-Schwartz J., Stollar B. D., Diener E. Treatment of lupus nephritis in adult (NZB + NZW)F1 mice by cortisone-facilitated tolerance to nucleic acid antigens. J Clin Invest. 1978 Feb;61(2):276–286. doi: 10.1172/JCI108937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bruneau C., Benveniste J. Circulating DNA:anti-DNA complexes in systemic lupus erythematosus. Detection and characterization by ultracentrifugation. J Clin Invest. 1979 Jul;64(1):191–198. doi: 10.1172/JCI109439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Conrad P. J., Lerner E. A., Murphy D. B., Jones P. P., Janeway C. A., Jr Differential expression of Ia glycoprotein complexes in F1 hybrid mice detected with alloreactive cloned T cell lines. J Immunol. 1982 Dec;129(6):2616–2620. [PubMed] [Google Scholar]
  6. Davidson W. F., Roths J. B., Holmes K. L., Rudikoff E., Morse H. C., 3rd Dissociation of severe lupus-like disease from polyclonal B cell activation and IL 2 deficiency in C3H-lpr/lpr mice. J Immunol. 1984 Aug;133(2):1048–1056. [PubMed] [Google Scholar]
  7. Hang L., Theofilopoulos A. N., Dixon F. J. A spontaneous rheumatoid arthritis-like disease in MRL/l mice. J Exp Med. 1982 Jun 1;155(6):1690–1701. doi: 10.1084/jem.155.6.1690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Inamura N., Hashimoto M., Nakahara K., Aoki H., Yamaguchi I., Kohsaka M. Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol. 1988 Jan;46(1):82–90. doi: 10.1016/0090-1229(88)90008-6. [DOI] [PubMed] [Google Scholar]
  9. Inamura N., Nakahara K., Kino T., Goto T., Aoki H., Yamaguchi I., Kohsaka M., Ochiai T. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. Transplantation. 1988 Jan;45(1):206–209. doi: 10.1097/00007890-198801000-00042. [DOI] [PubMed] [Google Scholar]
  10. Isenberg D. A., Snaith M. L., Morrow W. J., Al-Khader A. A., Cohen S. L., Fisher C., Mowbray J. Cyclosporin A for the treatment of systemic lupus erythematosus. Int J Immunopharmacol. 1981;3(2):163–169. doi: 10.1016/0192-0561(81)90007-2. [DOI] [PubMed] [Google Scholar]
  11. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., Imanaka H. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987 Sep;40(9):1249–1255. doi: 10.7164/antibiotics.40.1249. [DOI] [PubMed] [Google Scholar]
  12. Kubo C., Day N. K., Good R. A. Influence of early or late dietary restriction on life span and immunological parameters in MRL/Mp-lpr/lpr mice. Proc Natl Acad Sci U S A. 1984 Sep;81(18):5831–5835. doi: 10.1073/pnas.81.18.5831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mountz J. D., Smith H. R., Wilder R. L., Reeves J. P., Steinberg A. D. CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production. J Immunol. 1987 Jan 1;138(1):157–163. [PubMed] [Google Scholar]
  14. Ochiai T., Nakajima K., Nagata M., Suzuki T., Asano T., Uematsu T., Goto T., Hori S., Kenmochi T., Nakagoori T. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc. 1987 Feb;19(1 Pt 2):1284–1286. [PubMed] [Google Scholar]
  15. Okudaira H., Ogita T., Miyamoto T., Shiga J., Suko M., Okudaira K., Terada E., Ghoda A., Terada K., Saito M. Interstitial pneumonitis in autoimmune MRL/lpr mice and its treatment with cyclosporin A. Clin Immunol Immunopathol. 1986 Jan;38(1):47–54. doi: 10.1016/0090-1229(86)90121-2. [DOI] [PubMed] [Google Scholar]
  16. Smith H. R., Chused T. M., Steinberg A. D. Cyclophosphamide-induced changes in the MRL-lpr/lpr mouse: effects upon cellular composition, immune function, and disease. Clin Immunol Immunopathol. 1984 Jan;30(1):51–61. doi: 10.1016/0090-1229(84)90006-0. [DOI] [PubMed] [Google Scholar]
  17. Steinberg A. D., Roths J. B., Murphy E. D., Steinberg R. T., Raveche E. S. Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice. J Immunol. 1980 Aug;125(2):871–873. [PubMed] [Google Scholar]
  18. Theofilopoulos A. N., Balderas R. S., Shawler D. L., Lee S., Dixon F. J. Influence of thymic genotype on the systemic lupus erythematosus-like disease and T cell proliferation of MRL/Mp-lpr/lpr mice. J Exp Med. 1981 Jun 1;153(6):1405–1414. doi: 10.1084/jem.153.6.1405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Yoshida H., Kohno A., Ohta K., Hirose S., Maruyama N., Shirai T. Genetic studies of autoimmunity in New Zealand mice. III. Associations among anti-DNA antibodies, NTA, and renal disease in (NZB x NZW)F1 x NZW backcross mice. J Immunol. 1981 Aug;127(2):433–437. [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES